Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Collegium PharmaceuticalFRA:354 +3.36%78 ROC (Joel Greenblatt) % is 875.18% as of Mar. 2026, which is 806% above its 10-year median of 96.58. GuruFocus rates FRA:354 with a GF Score™ of 78/100 and a GF Value™ of €37.66. The stock has 3 warning signs investors should review. Among 982 Drug Manufacturers companies, Collegium Pharmaceutical ranks better than 99.59% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Collegium Pharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 875.18%.
The historical rank and industry rank for Collegium Pharmaceutical's ROC (Joel Greenblatt) % or its related term are showing as below:
FRA:354'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -10594.82 Med: 96.58 Max: 1078.21
Current: 1078.21
During the past 13 years, Collegium Pharmaceutical's highest ROC (Joel Greenblatt) % was 1078.21%. The lowest was -10594.82%. And the median was 96.58%.
FRA:354's ROC (Joel Greenblatt) % is ranked better than 99.59% of 982
companies
in the Drug Manufacturers industry
Industry Median: 11.45
vs FRA:354: 1078.21
Collegium Pharmaceutical's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 59.40% per year.
Collegium Pharmaceutical (FRA:354) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
Collegium Pharmaceutical ROC (Joel Greenblatt) % Related Terms
Collegium Pharmaceutical ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Collegium Pharmaceutical's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical ROC (Joel Greenblatt) % Chart
FRA:354 vs ALVO, PAHC, BIOA: ROC (Joel Greenblatt) % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical ROC (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's ROC (Joel Greenblatt) % falls into.
Collegium Pharmaceutical ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of 875.18% mean?
Collegium Pharmaceutical (FRA:354) has a ROC (Joel Greenblatt) % of 875.18% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Collegium Pharmaceutical and its competitors. This is 806% above median its historical median of 96.58. According to the industry distribution chart, Collegium Pharmaceutical ranks #4 out of 982 companies in the Drug Manufacturers industry, placing it in the top 0.40000000000001%.
Is Collegium Pharmaceutical's ROC (Joel Greenblatt) % too high?
Collegium Pharmaceutical's current ROC (Joel Greenblatt) % of 875.18% is 806% above median its 10-year median of 96.58. The Drug Manufacturers industry median ROC (Joel Greenblatt) % is 11.45. Collegium Pharmaceutical's value of 875.18% is 7543.5% above this industry median. Based on the distribution chart, Collegium Pharmaceutical ranks #4 out of 982 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Collegium Pharmaceutical has a GF Score™ of 78/100, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's ROC (Joel Greenblatt) % compare to ALVO and PAHC?
According to the Drug Manufacturers industry distribution chart, Collegium Pharmaceutical ranks #4 out of 982 companies for ROC (Joel Greenblatt) %. This places Collegium Pharmaceutical in the top 0% of its industry — outperforming the majority of peers. The industry median ROC (Joel Greenblatt) % is 11.45. Collegium Pharmaceutical's value of 875.18% is 7543.5% above this benchmark. While the company's 10-year median is 96.58 vs. the industry median of 11.45, Collegium Pharmaceutical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.45, based on 982 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Collegium Pharmaceutical's current ROC (Joel Greenblatt) % of 875.18% is 7543.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Collegium Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Collegium Pharmaceutical's current ROC (Joel Greenblatt) % is 875.18%, which is 806% above median its own 10-year median of 96.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Collegium Pharmaceutical (FRA:354) has a current ROC (Joel Greenblatt) % of 875.18%. The stock's GF Value™ is €37.66, compared to a current price of €30.80 — trading 18.2% below its estimated fair value. The current ROC (Joel Greenblatt) % is 875.18%, which is 806% above median its 10-year median of 96.58 and 7543.5% above the Drug Manufacturers industry median of 11.45. Collegium Pharmaceutical's overall GF Score™ is 78/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Collegium Pharmaceutical (FRA:354), the current ROC (Joel Greenblatt) % is 875.18% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Collegium Pharmaceutical (FRA:354) Overvalued in 2026?
Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued.
The current stock price of €30.80 is trading 18.2% below its estimated GF Value™ of €37.66.
Key valuation signals for FRA:354:
ROC (Joel Greenblatt) %: 875.18% (806% above median its 10-year median of 96.58)
GF Value™: €37.66 vs. price of €30.80 (18.2% below fair value)
Industry Position: 7543.5% above the Drug Manufacturers median (#4 of 982)
No single metric tells the full story. See the FRA:354 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
78GF Score
Get the complete analysis for FRA:354
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:354 has been successfully added to your 
